Report Overview

The European Melanoma Therapeutics market size stood at USD 0.72 billion in 2020 and is expected to rise to USD 2.39 billion by the end of 2028 exhibiting a CAGR of approximately 16.20% during the forecast period.

Melanoma is a type of cancer that arises from melanocytes which are the cells that secrete the pigment called melanin that is responsible for the colour of the skin. This is mostly caused by harmful ultraviolet radiation causing damage to the skin. Increased exposure to the sun or the radiation from tanning beds are the factors which leads up to the rise in incidence of melanoma. Out of all the tumours, malignant melanoma is the fifth most common. The European Melanoma Therapeutics market is the third largest market with a global share of 24%.

In 2018, there were more than 4700 invasive melanomas diagnosed in Sweden. The total incidence increase per year was more than 5 percent the last 10 years. The Melanoma Therapeutics market has witnessed an unparalleled boost in the market size, mainly due to the rapid development of melanoma treatments in the recent times.



Market Drivers

The Melanoma Therapeutics market in Sweden is mainly driven by the rise in melanoma cases in the country. There have been government initiatives to curb the development of disease as well as manage them which in turn drives the market growth in an unprecedented manner. This is supported by the increased per capita spending on healthcare in Sweden.

Melanoma treatment has developed rapidly leading the way for new technologies to curate new treatment procedures and premium products.

The increased demand of early and advanced melanoma treatments, compounded by a thriving patient base has generated an imminent need for improved treatment methods in the melanoma market which drives the pharmaceutical companies around the world to bring about a revolution in Therapeutics.